The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: UBS upgraded UiPath (PATH) to Neutral from Sell with a price target of $17, up from $10, as the firm resumed coverage of the stock. The outlook is "still mixed," but near-term GenAI risk fears appear "overdone," UBS tells investors.Needham upgraded TransMedics (TMDX) to Buy from Hold with a $148 price target. Need ...

Accessibility StatementSkip Navigation NEW YORK, Oct. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Hologic, Inc. (NASDAQ: HOLX) related to its sale to funds managed by Blackstone and TPG. U ...

Core Viewpoint - Hologic, Inc. is undergoing a proposed sale to Blackstone and TPG, valued at up to $18.3 billion, which has led to a downgrade of its stock rating by William Blair from "Outperform" to "Market Perform" [1][2][6] Company Overview - Hologic, Inc. specializes in medical diagnostics and devices within the women's health sector [1] - The company is currently trading at $74.16, reflecting a 3.18% increase from the previous day [4] - Hologic's stock has fluctuated between a high of $84.39 and a low of $51.90 over the past year, with a market capitalization of approximately $16.49 billion [4][6] Acquisition Details - The proposed acquisition involves purchasing all outstanding shares of Hologic at $76 per share, with potential additional payments through a non-tradable contingent value right [2][3] - The deal offers Hologic shareholders a total of $76.00 per share in cash, plus up to $3.00 more through contingent value rights [2] Market Activity - Today's trading volume for Hologic is notably high at 13.85 million shares, indicating strong investor interest amid ongoing acquisition discussions [5][6]

Accessibility StatementSkip Navigation We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts Ademi & Fruchter LLP Guri AdemiToll Free: (866) 264-3995Fax: (414) 482-8001 MILWAUKEE, Oct. 21, 2025 /PRNewswire/ -- The Ademi Firm is investigating Hologic (Nasdaq: HOLX) for possible breaches of fiduciary duty and other violations of law ...

Core Insights - Hologic (HOLX) and Idexx Laboratories (IDXX) are both considered by investors interested in Medical - Instruments stocks, with a focus on determining which stock is more attractive to value investors [1] Valuation Metrics - Both HOLX and IDXX currently hold a Zacks Rank of 2 (Buy), indicating positive revisions to their earnings estimates and improving earnings outlooks [3] - HOLX has a forward P/E ratio of 16.05, while IDXX has a significantly higher forward P/E of 51.02 [5] - The PEG ratio for HOLX is 2.47, compared to IDXX's PEG ratio of 4.17, suggesting that HOLX may be undervalued relative to its expected earnings growth [5] - HOLX's P/B ratio is 3.3, while IDXX's P/B ratio is 35.29, further indicating that HOLX is more attractively valued [6] - Based on these valuation metrics, HOLX receives a Value grade of B, whereas IDXX receives a Value grade of D, suggesting that HOLX is the superior value option at this time [6]

SUSTAINABILITY: This Mag 7 Member Targets AI Data Centers And All-Renewable ElectricityHologic (HOLX) on Tuesday said it agreed to be acquired by Blackstone and TPG in a take-private deal that values the women's health tech company at up to $18.3 billion.The news comes as little surprise. There has been speculation since May and even more recent reports in September. Reports last week suggested Blackstone and TPG offered $16 billion for Hologic, but the company turned down the offer, Needham analyst Mike Ma ...

Private equity firms Blackstone (BX) and TPG (TPG) will spend more than $13 billion to buy women’s health specialist Hologic. The companies said Tuesday they will pay up to $79 for each Hologic share in a deal that takes the company private. Shares of Hologic (HOLX) rose after markets opened Tuesday. The companies said the price represents a premium of about 46% to the stock’s closing price in late May, before media reports surfaced about a possible deal. The terms include $76 in cash for each share plu ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Hologic, Inc. (NASDAQ: HOLX) to funds managed by Blackstone and TPG is fair to Hologic shareholders. Under the terms of the proposed transaction, Hologic shareholders will receive $76.00 per share in cash plus a non-tradable contingent value right to receive up to $3.00 per share in two payments of up to $1.50 each. Halper Sadeh encourages Hologic shareholders to click here to learn mo. ...

Under the terms of the deal, Blackstone and TPG agreed to acquire all outstanding shares of the women's-health company for $76 apiece in cash. ...

Blackstone and TPG have agreed to acquire medical diagnostics firm Hologic in an up to $18.3 billion deal, the company said on Tuesday. ...